Establishment Labs Holdings Inc. (NASDAQ:ESTA – Get Rating) was the target of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 752,700 shares, a decrease of 25.5% from the March 15th total of 1,010,000 shares. Based on an average daily volume of 155,700 shares, the days-to-cover ratio is presently 4.8 days.
Several brokerages have commented on ESTA. The Goldman Sachs Group lowered their target price on Establishment Labs from $78.00 to $67.00 and set a “neutral” rating for the company in a research note on Monday, March 21st. Zacks Investment Research downgraded Establishment Labs from a “hold” rating to a “sell” rating in a research note on Friday, March 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $84.40.
In other Establishment Labs news, major shareholder Jw Asset Management, Llc bought 35,000 shares of the stock in a transaction on Wednesday, April 13th. The stock was purchased at an average price of $70.01 per share, with a total value of $2,450,350.00. Following the completion of the purchase, the insider now owns 3,177,485 shares in the company, valued at $222,455,724.85. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders have purchased 60,000 shares of company stock valued at $3,868,100 in the last ninety days. 13.08% of the stock is currently owned by company insiders.
Shares of ESTA traded down $0.13 during trading hours on Monday, reaching $71.74. The stock had a trading volume of 9,087 shares, compared to its average volume of 151,851. Establishment Labs has a 12 month low of $46.93 and a 12 month high of $88.66. The stock’s 50-day moving average is $60.90. The company has a quick ratio of 2.66, a current ratio of 3.55 and a debt-to-equity ratio of 1.02.
Establishment Labs (NASDAQ:ESTA – Get Rating) last issued its quarterly earnings data on Tuesday, March 1st. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.27). Establishment Labs had a negative net margin of 32.47% and a negative return on equity of 64.87%. During the same period in the prior year, the firm earned ($0.23) EPS. On average, analysts expect that Establishment Labs will post -1.27 EPS for the current year.
About Establishment Labs (Get Rating)
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution.
- Get a free copy of the StockNews.com research report on Establishment Labs (ESTA)
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.